5 Fluororacil Alone versus 5 Fluororacil plus folinic acid in the treatment of colorectal carcinoma: metanalysis and review of the literature

Title5 Fluororacil Alone versus 5 Fluororacil plus folinic acid in the treatment of colorectal carcinoma: metanalysis and review of the literature
Publication TypeJournal Article
Year of Publication2000
AuthorsLo Bello, L., G. Pistone, S. Restuccia, E. Vinci, G. Mazzoleni, and M. Malaguarnera
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume38
Pagination553-562
Date Published12/2000
ISSN0946-1965
Abstract

Objective: Innovative techniques in the field of artificial intelligence could help to resolve several methodological problems. A model taking into account all the parameters involved in a therapy can foresee the results of each type of treatment or therapeutic protocol on patients at different stages of a disease. We used a Computer Decision Support System in order to verify the reliability and efficacy of this method on chemotherapy of colorectal carcinoma. Material and methods: We analyzed 8 randomized clinical trials employing 5-fluorouracil alone (5-FU) or 5-fluorouracil (5-FU) plus leucovorin (FA) in the management of advanced colorectal carcinoma. Computer Decision Support System (CDSS) was used to perform four basic tasks: data acquisition and organization; data recruitment; combination of the various principles and specific data; user-friendly display of the analysis results and responses to treatment. Results: In the majority of the studies examined, the death rates were lower in patients treated with 5-FU + FA than in those on 5-FU alone, even though the difference was not statistically significant. However, there were wide fluctuations in the efficacy/ tolerability ratio between the two protocols investigated, depending on the patients’ clinical status. Our data showed that a strong attack using 5-FU + FA is feasible whenever the patients’ clinical conditions are not particularly severe, whereas a moderate attack using 5-FU alone is recommended as the patients’ clinical condition worsens. Conclusion: The use of CDSS in the management of colorectal carcinoma indicates which therapy is the best in terms of efficacy, overall survival and incidence of side effects.

URLhttp://www.dustri.com/nc/journals-in-english/mag/int-journal-of-clinical-pharmacology-and-therapeutics/vol/volume-38/issue/december-16.html